In the last trading session, 1.71 million shares of the Bioline Rx Ltd ADR (NASDAQ:BLRX) were traded, and its beta was 1.46. Most recently the company’s share price was $0.46, and it changed around -$0.04 or -8.91% from the last close, which brings the market valuation of the company to $36.80M. BLRX currently trades at a discount to its 52-week high of $1.93, offering almost -319.57% off that amount. The share price’s 52-week low was $0.50, which indicates that the current value has fallen by an impressive -8.7% since then. We note from Bioline Rx Ltd ADR’s average daily trading volume that its 10-day average is 0.4 million shares, with the 3-month average coming to 270.80K.
Bioline Rx Ltd ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BLRX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Bioline Rx Ltd ADR is expected to report earnings per share of -0.1 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bioline Rx Ltd ADR (NASDAQ:BLRX) trade information
Instantly BLRX has showed a red trend with a performance of -8.91% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.6690 on recent trading dayincreased the stock’s daily price by 31.24%. The company’s shares are currently down -70.70% year-to-date, but still down -25.81% over the last five days. On the other hand, Bioline Rx Ltd ADR (NASDAQ:BLRX) is -25.20% down in the 30-day period. We can see from the shorts that 0.18 million shares have been sold at a short interest cover period of 0.86 day(s).
Bioline Rx Ltd ADR (BLRX) estimates and forecasts
Bioline Rx Ltd ADR share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -43.27 percent over the past six months and at a 73.40% annual growth rate that is well above the industry average of 19.40%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 66.70% in revenue this quarter, and will report an increase of 33.30% in the next quarter. The year-over-year growth rate is expected to be 322.70%, up from the previous year.
Consensus estimates provided by 3 financial analysts predict the company will bring in an average of 4.12M in revenue for the current quarter. 3 analysts expect Bioline Rx Ltd ADR to make 4.74M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at -1.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.53%.
BLRX Dividends
Bioline Rx Ltd ADR’s next quarterly earnings report is expected to be released in November.
CVI HOLDINGS, LLC, with 1.126% or 0.82 million shares worth $0.46 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
